Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) and Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.
Risk and Volatility
Enlivex Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Bright Minds Biosciences has a beta of -6.52, meaning that its stock price is 752% less volatile than the S&P 500.
Insider & Institutional Ownership
1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enlivex Therapeutics | N/A | N/A | -$29.07 million | ($0.98) | -1.17 |
| Bright Minds Biosciences | N/A | N/A | -$5.47 million | ($0.50) | -77.78 |
Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Enlivex Therapeutics and Bright Minds Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enlivex Therapeutics | 0 | 0 | 2 | 1 | 3.33 |
| Bright Minds Biosciences | 0 | 0 | 3 | 1 | 3.25 |
Enlivex Therapeutics presently has a consensus target price of $9.50, suggesting a potential upside of 729.69%. Bright Minds Biosciences has a consensus target price of $80.00, suggesting a potential upside of 105.71%. Given Enlivex Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Enlivex Therapeutics is more favorable than Bright Minds Biosciences.
Profitability
This table compares Enlivex Therapeutics and Bright Minds Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enlivex Therapeutics | N/A | -67.57% | -58.45% |
| Bright Minds Biosciences | N/A | -58.55% | -53.79% |
Summary
Bright Minds Biosciences beats Enlivex Therapeutics on 7 of the 11 factors compared between the two stocks.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
About Bright Minds Biosciences
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
